CAR-T cell therapy for children with hard-to-treat rheumatic diseases
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 5 years old.
- You need to have a severe form of a rheumatic disease that hasn't gotten better with standard medicines.
- Your B cells (a type of immune cell) must be high enough in your blood.
- Your heart, kidneys, liver, and lungs need to be working well enough for the procedure.
- You cannot have had a CAR-T treatment before, unless it stopped working.
- You must be willing to use birth control if you're of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests a treatment using your own immune cells, modified to target a protein called CD19, for children and teens with juvenile dermatomyositis that hasn't gotten better with standard treatments. The goal is to see if this therapy can help calm the inflammation and improve symptoms.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Hear when a new Polyarticular Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.